{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T21:00:38Z","timestamp":1720299638325},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.critrevonc.2010.09.008","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T04:25:24Z","timestamp":1294892724000},"page":"e42-e48","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Biologic tools to personalize treatment in genitourinary cancers"],"prefix":"10.1016","volume":"84","author":[{"given":"Sergio","family":"Bracarda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Sisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Del Buono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ori","family":"Ishiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2010.09.008_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.critrevonc.2010.09.008_bib0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2407-9-34","article-title":"Metastatic renal cell cancer treatments: an indirect comparison meta-analysis","volume":"9","author":"Mills","year":"2009","journal-title":"BMC Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2010.09.008_bib0015","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"March\u2013April (Suppl. 1)","key":"10.1016\/j.critrevonc.2010.09.008_bib0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/01926230490425021","article-title":"Development and use of biomarkers in oncology drug development","volume":"32","author":"Floyd","year":"2004","journal-title":"Toxicol Pathol"},{"issue":"18","key":"10.1016\/j.critrevonc.2010.09.008_bib0025","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1200\/JCO.2008.19.7939","article-title":"Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial","volume":"27","author":"Dowsett","year":"2009","journal-title":"J Clin Oncol"},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2010.09.008_bib0030","first-page":"766","article-title":"Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer","volume":"361","author":"BIG 1-98 Collaborative Group","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.09.008_bib0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-months analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"issue":"September 25\u2013October 1 (9440)","key":"10.1016\/j.critrevonc.2010.09.008_bib0040","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.critrevonc.2010.09.008_bib0045","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/annonc\/mdq037","article-title":"Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer","volume":"21","author":"Rajpar","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.008_bib0050","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.4048","article-title":"(Q)-TwiST analysis of trastuzumab plus fluoropyrimidine\/cisplatin (T-XP\/FP) versus XP\/FP alone as first-line therapy for advanced HER-2positive gastric cancer","volume":"28","author":"Chung","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.critrevonc.2010.09.008_bib0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/annonc\/mdm490","article-title":"Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel","volume":"19","author":"Domingo-Domenech","year":"2008","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.09.008_bib0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djm252","article-title":"HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials","volume":"100","author":"Gennari","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.critrevonc.2010.09.008_bib0065","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ijrobp.2007.04.070","article-title":"Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202","volume":"69","author":"Che","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.09.008_bib0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.eururo.2008.06.038","article-title":"Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy","volume":"56","author":"Helley","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.09.008_bib0075","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/pros.20016","article-title":"Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer","volume":"59","author":"Eaton","year":"2004","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.09.008_bib0080","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1200\/JCO.2004.07.022","article-title":"Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy","volume":"22","author":"Chan","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3 Pt 1","key":"10.1016\/j.critrevonc.2010.09.008_bib0085","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.juro.2007.05.018","article-title":"Chromogranin A expression in patients with hormone na\u00efve prostate cancer predicts the development of hormone refractory disease","volume":"178","author":"Berruti","year":"2007","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.09.008_bib0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0302-2838(03)00303-8","article-title":"Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy","volume":"44","author":"Kamiya","year":"2003","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.09.008_bib0095","first-page":"2533","article-title":"Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study","volume":"61","author":"Bork","year":"2001","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.09.008_bib0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11864-007-0031-3","article-title":"Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer","volume":"8","author":"Haas","year":"2007","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.008_bib0105","series-title":"ASCO Genitourinary Cancers Symposium","article-title":"Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-\u03b12a (IFN) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC Study 0681","author":"Bracarda","year":"2008"},{"issue":"22","key":"10.1016\/j.critrevonc.2010.09.008_bib0110","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2010.09.008_bib0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11912-010-0085-4","article-title":"Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors","volume":"12","author":"Vaziri","year":"2010","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.09.008_bib0120","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1464-410X.2010.09218.x","article-title":"Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy","volume":"106","author":"Choueiri","year":"2010","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/j.critrevonc.2010.09.008_bib0125","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/ki.2009.552","article-title":"Predictive value of baseline serum vascular andothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib","volume":"77","author":"Porta","year":"2010","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.critrevonc.2010.09.008_bib0130","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/sj.bjc.6605409","article-title":"Identification of TNF-alpha and MMP-9 as potential predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array","volume":"101","author":"Perez-Gracia","year":"2009","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2010.09.008_bib0135","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bjc.6605563","article-title":"Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma","volume":"102","author":"Jeppesen","year":"2010","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.09.008_bib0140","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/CJI.0b013e3181a950e5","article-title":"Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80\/86+ T cells indicates adverse outcome","volume":"32","author":"Westermann","year":"2009","journal-title":"J Immunother"},{"issue":"5","key":"10.1016\/j.critrevonc.2010.09.008_bib0145","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1442-2042.2009.02289.x","article-title":"Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens","volume":"16","author":"Miyake","year":"2009","journal-title":"Int J Urol"},{"issue":"16","key":"10.1016\/j.critrevonc.2010.09.008_bib0150","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2008.19.1106","article-title":"Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy","volume":"27","author":"Sabatino","year":"2009","journal-title":"J Clin Oncol"},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2010.09.008_bib0160","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.critrevonc.2008.06.002","article-title":"Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents","volume":"69","author":"Bellmunt","year":"2009","journal-title":"Crit Rev Hematol Oncol"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.09.008_bib0165","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bjc.6602073","article-title":"Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer","volume":"91","author":"Matsumoto","year":"2004","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2010.09.008_bib0170","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.urolonc.2008.03.016","article-title":"XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy","volume":"27","author":"Pinho","year":"2009","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.09.008_bib0175","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.juro.2007.07.118","article-title":"The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study","volume":"178","author":"Yutkin","year":"2007","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.09.008_bib0180","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.eururo.2009.01.040","article-title":"Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"55","author":"Avari","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.09.008_bib0185","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/annonc\/mdl435","article-title":"Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy","volume":"18","author":"Bellmunt","year":"2007","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.critrevonc.2010.09.008_bib0190","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/1078-0432.CCR-06-0595","article-title":"Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer","volume":"12","author":"Kitamura","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.09.008_bib0195","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eururo.2006.06.006","article-title":"HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours","volume":"51","author":"Lebret","year":"2007","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.09.008_bib0200","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/jjco\/hyh026","article-title":"Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer","volume":"34","author":"Matsumoto","year":"2004","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"10.1016\/j.critrevonc.2010.09.008_bib0205","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/cncr.20200","article-title":"p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach","volume":"100","author":"Garcia del Muro","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2010.09.008_bib0210","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1158\/1078-0432.CCR-09-2042","article-title":"Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial","volume":"16","author":"Riethdorf","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.09.008_bib0215","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","article-title":"Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data","volume":"10","author":"Scher","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.008_bib0220","article-title":"Disseminated and circulating tumor cells: role in effective cancer management","author":"Lin","year":"2010","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842810002222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842810002222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T16:25:40Z","timestamp":1559924740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842810002222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":43,"alternative-id":["S1040842810002222"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2010.09.008","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}